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indoleamine 2,3-Dioxygenase and 
Tolerance: where Are we now?
Andrew L. Mellor*, Henrique Lemos and Lei Huang
Faculty of Medical Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Cells expressing IDO suppress innate and adaptive immunity to promote tolerance by 
catabolizing the amino acid tryptophan (Trp) and other indole compounds. Interferon 
type I (IFN-I) and type II (IFN-II) produced at sites of inflammation or by activated immune 
cells are potent IDO inducers because mammalian IDO genes contain IFN response 
elements. Elevated IDO expression by dendritic cells (DCs) is of particular significance 
because IDO activity converts mature DCs into tolerogenic APCs that suppress effec-
tor T cells (Teff) and promote regulatory T cells (Tregs), thereby promoting tolerance. 
Local Trp depletion and production of immune suppressive Trp catabolites contribute 
to tolerogenic processes by activating metabolic pathways responsive to amino acid 
withdrawal and aryl hydrocarbon signaling, respectively. Sustained IDO elevation cre-
ates local immune privilege that protects tissues from immune-mediated damage and 
allows tissues to heal. This response occurs in lymphoid tissues when DNA released 
by dying tissue cells is sensed to induce specialized DC subsets to acquire tolero-
genic phenotypes. The tolerogenic effects of IDO also promote tumorigenesis and 
help establish immune checkpoints in cancer, as malignant cells are protected from 
immune surveillance. Similar processes may attenuate host immunity to some patho-
gens that persist in immunocompetent individuals. However, if inflammation with IDO 
involvement is not resolved, chronic immune activation at such sites causes progressive 
tissue damage over time. Another effect of sustained IDO activity is enhanced pain 
sensitivity, as some Trp catabolites produced by cells expressing IDO are neuroactive. 
In this review, we summarize links between IDO and chronic inflammatory diseases 
and discuss prospects for exploiting IDO and Trp catabolism to suppress immunity and 
promote tolerance for clinical benefit, with particular emphasis on protecting tissues 
from destructive autoimmunity.
Keywords: indoleamine 2,3-dioxygenase, tolerance, autoimmunity, nociceptive pain, transplant, transplantation 
immunology
inTRODUCTiOn
Higher mammals possess two closely linked and homologous genes encoding indoleamine 
2,3-dioxygenase (IDO1, IDO2), which catabolizes compounds containing indole rings, including 
tryptophan (Trp) and the neurotransmitter serotonin, aka 5-hydroxytryptamine (5HT). IDO1 gene 
expression is responsive to interferons (IFNs), explaining why IDO activity is elevated in many 
inflammatory settings, including infectious, allergic and autoimmune (AI) diseases, tumorigenesis, 
and pregnancy. In this brief review, we highlight key aspects of IDO1 immunobiology and sum-
marize prospects for exploiting this pathway to protect tissues from immune-mediated damage in 
FigURe 1 | The Kynurenine pathway. IDO catabolizes indole compounds, 
including Trp and 5-hydroxytryptamine. Enzymes (blue) downstream of IDO 
generate bioactive catabolites called kynurenines. Immune and CNS cells 
express sensors (red) that detect these metabolic changes to impact 
immunologic and neurologic processes.
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patients with AI syndromes and transplanted tissues. The concise 
format of this review precludes a comprehensive overview and 
readers are directed elsewhere for detailed discussions of the cur-
rent state of this highly active field. The ability of cells expressing 
IDO1 genes to suppress immune responses was first described 
almost 20 years ago (1). Since then, research on IDO has blos-
somed and IDO inhibitors are promising immune checkpoint 
inhibitor drugs to enhance cancer immunotherapy (2, 3).
iFns, iDO, AnD iMMUne BALAnCe
Interferons released at sites of inflammation stimulate hundreds 
of downstream genes, known collectively as IFN-stimulated 
genes (ISGs). Historically, ISGs that activate immune cells 
to incite immunity to infections have been the major focus of 
research. However, some ISGs activate immune regulatory cells 
to promote tolerogenic, rather than immunogenic processes. 
The local balance of immunogenic and tolerogenic responses to 
IFNs is a key factor driving the effects of local inflammation on 
immune responses and tissue functions.
IDO1 is an example of a tolerogenic ISG because IDO sup-
presses immune responses and the IDO1 gene is responsive to both 
IFN type I (IFN-I) and type II (IFN-II). IFN response elements 
called ISRE and GAS sequences, which confer responsiveness to 
IFN-I and IFN-II signaling, respectively, are located in mamma-
lian IDO1 gene promoters. Though most cell types express IFN 
receptors, IFNs induce IDO only in select cell types because IFN 
signaling is regulated in some cells. For example, discrete subsets 
of dendritic cells (DCs) from humans and mice are competent 
to express IDO when exposed to IFNs (4). Importantly, IDO1 
gene transcription may not enhance IDO enzyme activity due 
to posttranslational controls, such as limited access to hemin, an 
IDO enzyme co-factor, local redox status, and nitric oxide, which 
inhibits heme/O2 conjugation needed to break indole structures 
(5, 6). IDO can also promote tolerance via non-catalytic signaling 
to induce TGFβ release by some DCs (7). Thus, whether IDO 
activity manifests in inflamed tissues depends on many factors, 
linked to the complexity of biochemical pathways and cell inter-
actions driving responses to IFNs in tissues. Thus, it is important 
to study responses to IFNs in physiologic settings, where multiple 
effects are integrated to generate particular responses to inflam-
matory insults. Though much can be learned by studying how 
cultured or physiologic cells and isolated tissues respond to IFNs, 
these approaches cannot predict physiologic outcomes accurately 
in the absence of the full panoply of biochemical processes and 
cellular interactions that exist in inflamed tissues.
iDO AnD Trp CATABOLiSM
IDO catalyzes the initial, rate-limiting step in oxidative 
catabolism of compounds containing indole rings (Figure  1), 
including Trp and 5HT. Cells expressing IDO1 genes deplete 
Trp and generate bioactive catabolites, known as kynurenines, 
after the catabolite kynurenine (Kyn). Enzymes downstream 
of IDO further degrade Kyn to generate kynurenic acid (KA), 
3-hydroxy-anthranilic acid (HAA), quinolinic acid (QA), niacin, 
and other catabolites. Some immune cells can sense Trp depletion 
or catabolites to suppress innate and adaptive immunity and 
promote tolerogenic responses. Limiting access to Trp activates 
the ribosomal kinase GCN2, which senses binding of uncharged 
tRNA to ribosomes. Activated GCN2 triggers the integrated 
stress response (ISR) to amino acid withdrawal, which induces 
CHOP gene expression but shuts down most gene transcrip-
tion to promote cell autophagy. The ISR blocks cell cycle entry 
by TCR-activated T  cells and activates resting Foxp3-lineage 
regulatory CD4 T cells (Tregs) to promote tolerogenic responses 
to inflammatory signals from immune adjuvants and tumor vac-
cines (8). Some catabolites in the Kyn pathway bind to receptors 
expressed by immune cells to promote tolerogenic responses. 
For example, HAA, Kyn, and KA suppress T  cell responses by 
binding to PDK1 or aryl hydrocarbon receptors (AhR) in T cells, 
APCs, or other immune cells. As well as influencing inflamma-
tory and immunologic processes, the Kyn pathway also drives 
neurologic comorbidities such as pain, depression, and fatigue, 
commonly associated with chronic inflammatory disease. By 
consuming Trp, the substrate for 5HT and melatonin synthesis, 
IDO impacts mood and promotes depression. Moreover, recep-
tors such as NMDA, α7AChR, and Gpr35 expressed by neuronal 
cells can sense neuroactive catabolites such as KA and QA. An 
intriguing link between physical exercise and reduced depres-
sion was reported due to increased uptake of circulating Kyn 
by PGC1a1 receptors expressed by active skeletal muscles (9). 
Niacin, another product of the kynurenine pathway that binds 
to the Gpr109a receptor, also suppresses colonic inflammation 
and carcinogenesis to promote gut homeostasis and health (10). 
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Collectively, these points reveal pivotal roles for the Kyn pathway 
as a critical modifier of immunologic and neurologic responses 
to inflammation via the biochemical effects of catabolizing indole 
compounds such as Trp and 5HT.
CHROniC inFLAMMATORY  
DiSeASe AnD iDO
Elevated IDO activity manifests in many chronic inflammatory 
syndromes, including cancer, infections, AI and allergic diseases, 
transplant rejection, and pregnancy (11). A link between IDO and 
immune regulation was first described in pregnancy. IDO inhibi-
tors applied to pregnant mice induced allogeneic fetal rejection 
by maternal T cells, while sparing syngeneic fetus’ from the same 
fate (1), indicating that IDO stops maternal T cells from attacking 
fetal allografts during pregnancy. Further studies revealed that 
complement activation drove fetal allograft rejection when IDO 
was inhibited, indicating that IDO blocks complement activation 
by maternal T cells responsive to fetal alloantigens (12).
iDO and Hypo-immune Syndromes
IDO expression is often elevated in inflamed tumor microenvi-
ronments in mice and humans. Tumor cells or tumor-associated 
cells in malignant lesions may express IDO. Elevated IDO may 
also manifest in local lymph nodes draining sites of tumor growth. 
The paradigm that IDO promotes tolerogenic responses suggests 
that elevated IDO activity during tumorigenesis contributes to 
robust tumor resistance to natural and vaccine-induced anti-
tumor immunity. Consistent with this notion, IDO inhibitors 
enhance tumor immunity to retard tumor growth in several 
mouse models, identifying IDO as a cancer immune checkpoint. 
Consequently, IDO inhibitors are under scrutiny as potential 
immune checkpoint inhibitor drugs in ongoing clinical trials 
in cancer patients. Early indications are that IDO inhibitors are 
well tolerated and may enhance clinical response rates to some 
cancers. However, heightened risk of inciting autoimmunity may 
be an undesirable side effect, as for other immune checkpoint 
inhibitors. Similarly, IDO induced by infectious pathogens may 
attenuate host immune responses. Most infections induce rapid 
IDO upregulation since IFN-I is a common innate response to 
many bacterial, viral, fungal, and parasitic infections. Largely, 
this is because Toll-like receptors (TLRs) and nucleic acid sensors 
that recognize pathogen-associated molecular patterns stimulate 
IFN-I production at sites of infection. Some pathogens that cause 
chronic infections may exploit the Kyn pathway to promote per-
sistence in immunocompetent individuals. Consistent with this 
paradigm, IDO inhibitors reduced Leishmania major burdens in 
mice, even when applied at the peak of infection (13, 14). IDO 
inhibitors also reduced lentiviral HIV-1 burdens in a mouse 
model of HIV-1 encephalitis, suggesting that robust IDO induc-
tion on HIV-1 infection attenuates host immunity (15). However, 
opposing protective effects of IDO for hosts and pathogens were 
observed in distinct models of infection in mice. For example, 
IDO inhibition induced uniform mortality of mice infected with 
the parasite Toxoplasma gondii (14), consistent with earlier work 
showing that IDO contributes to innate host resistance to some 
pathogens such as parasitic Toxoplasma and fungal Candida 
infections. Moreover, despite >100-fold increase in lung IDO 
activity during influenza infections in mice, IDO ablation had 
no impact on virus burdens and only nuanced effects on host 
T cell responses to influenza infection (16). Thus, interventions 
to boost host immunity to pathogens by manipulating the Kyn 
pathway must be investigated thoroughly to avoid potential 
undesirable consequences.
iDO and Hyper-immune Syndromes
Elevated IDO activity also manifests in many AI and allergic syn-
dromes in mice and humans. IDO attenuates AI progression in 
several mouse models of type I diabetes, multiple sclerosis (MS), 
rheumatoid arthritis (RA), systemic lupus erythematosus, and 
graft-versus-host disease since IDO1 gene ablation potentiated 
disease onset and severity mediated by T  cells, while enhanc-
ing IDO1 gene expression attenuated disease progression and 
severity (2). One exception is the KxBN arthritis model driven 
by AI B cells, potentially because IDO and IL6 (aka B cell growth 
factor) co-promote B  cell autoimmunity in this model (17). 
IDO may also have equivocal roles in allergic diseases, as Th2-
mediated allergic airway inflammation in mice was attenuated 
by treating mice with TLR9 ligands (CpGs) to induce IDO and 
by ablating IDO1 genes (18, 19). The reason for this discrepancy 
is unknown, though distinct cell types expressing IDO may pro-
mote or attenuate allergic disease. This point is important when 
considering potential roles for IDO in immune responses, as 
several cell types may express IDO and mediate diametric effects 
on immune responses in particular inflammatory settings.
USing iDO inDUCeRS TO  
PROMOTe TOLeRAnCe
The tolerogenic effects of cells expressing IDO have prompted 
efforts to boost IDO activity, particularly in DCs, as novel 
strategies to alleviate AI disease and prolong transplant survival. 
A number of strategies can be envisaged to exploit these proper-
ties for clinical benefit, as described below.
iDO1 gene Transduction
In transplantation, proof-of-principle emerged from several 
studies on rodent models of lung engraftment showing that 
pre-transplant IDO1 gene transduction promoted robust lung 
allograft survival in the absence of global immune suppressants 
(20–22). Moreover, CD8+ T  cells infiltrating IDO1-transduced 
lungs exhibited impaired effector functions due to selective 
IDO-mediated inhibition of mitochondrial electron transfer 
(20), a finding reminiscent of functional impairment of tumor-
infiltrating T  cells in cancer. It is unclear from these reports if 
lung allograft survival was dependent on sustained IDO activity 
to suppress alloimmunity or if stable tolerance to donor alloanti-
gens not requiring sustained IDO1 gene expression was induced 
post-transplantation. Nevertheless, as in pregnancy, these studies 
reveal that elevated IDO activity protects healthy tissues from 
immune-mediated destruction. However, as gene transduction 
in clinical settings is complicated technically and raises serious 
4Mellor et al. IDO and Tolerance
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1360
risks, a key question is how to elevate and, as may be necessary, 
to sustain IDO in order to protect healthy tissues in patients.
Soluble CTLA4
A potential alternative strategy is to use drugs to induce IDO. 
Several IDO inducing drugs are known, including soluble 
CTLA4, TLR ligands, and DNA. The immunosuppressant drug 
Abatacept (Orencia™) is a soluble CTLA4 molecule that blocks 
CD28-mediated T  cell co-stimulation. Abatacept is used to 
alleviate RA in some patients and may help alleviate other AI 
syndromes, though treatments are expensive. In mice, soluble 
CTLA4 reagents induced specialized DC subsets to express 
IDO1 genes and acquire potent tolerogenic functions via “reverse 
signaling” mediated by CD80/86 (B7) surface ligands on DCs 
that bind CD28 and CTLA4 on T cells (23, 24). It is unclear how 
B7 molecules stimulate DCs to express IDO1 genes but IFN-I 
signaling and critical functions in the Fc (Ig) domain of soluble 
CTLA4 were required for this response. Commercial products 
like Orencia were optimized for CD28 binding and bio-availa-
bility. Consequently, these reagents may have lost the ability to 
induce IDO if critical Fc (Ig) domain functions were engineered 
out. Reverse signaling via other ligand-receptor pathways (e.g., 
GITR, ICOS, CD200) to induce DCs to express IDO has also been 
shown to cause DCs to adopt tolerogenic phenotypes (25–27).
TLR Ligands
TLR4 (LPS) and TLR9 (CpGs) ligands also induce DCs to express 
IDO. Thus, CpGs given systemically to mice activated resting 
Tregs to suppress effector T  cell responses via a mechanism 
dependent on IDO1 gene expression by discrete splenic DC 
subsets. In contrast, CpG treatments induced resting Tregs to 
convert into Th17 T cells when IDO1 genes were ablated, identi-
fying DCs as pivotal regulators of tolerogenic and immunogenic 
responses to TLR9 ligands contingent on if DCs were induced to 
express functional IDO or not, respectively. However, co-induced 
pro-inflammatory and consequent immunogenic responses to 
TLR ligands may overcome tolerogenic responses, especially in 
inflamed tissues.
Stimulator of iFn genes (STing) Agonists
Systemic treatments with DNA nanoparticles (DNPs) induced 
IDO in many mouse tissues. In spleen, myeloid DCs ingested 
DNPs and sensed cargo DNA to activate the STING adaptor, a 
potent IFN-I inducer (28, 29). Consistent with these findings 
DNPs alleviated AI disease progression in mouse models of RA 
and MS (EAE) and therapeutic responses to DNPs depended on 
STING-IFN-I signaling to induce IDO in DCs (28, 30). Moreover, 
synthetic cyclic dinucleotides (CDNs) that mimic natural STING 
agonists generated by the cytosolic DNA sensor cyclic guanyl-
adenyl diphosphate (cGAMP) synthase (cGAS) also alleviated 
AI syndromes in mice (30). Paradoxically, CDNs administered 
directly into developing tumors stimulated potent anti-tumor 
immunity that attenuated tumor growth in mice (31). Diametric 
responses to CDNs in AI and tumor models emphasize the critical 
importance of dosing since systemic and intra-tumoural delivery 
of CDNs was required to induce tolerogenic and immunogenic 
responses, respectively, in these distinct inflammatory settings.
interferons
In principle, IFN-I could also be used to induce IDO1-dependent 
tolerogenic responses since IFN-I mediated such responses to 
B7, TLR, and STING ligands. Indeed, some therapeutic effects 
of IFN-I (IFNβ) in MS patients may accrue from tolerogenic 
responses mediated via IDO, though it is unclear if this does 
occur. As with TLR ligands, undesirable pro-inflammatory 
(immunogenic) responses to IFN-I (or IFN-II) may predominate 
and overcome tolerogenic responses mediated by IDO, making 
the clinical use of IFNs to induce tolerance high risk.
iDO PAin AnD DePReSSiOn
As stated above, the Kyn pathway has profound effects on neu-
rologic, as well as inflammatory and immunologic, processes. 
The KA:QA balance is a major factor in neuro-inflammatory 
syndromes, as high QA levels correlate with neuro-toxicities 
and dementia, while KA ameliorates these damaging effects. 
Heightened and sustained IDO activity during chronic inflam-
matory diseases may contribute to enhanced pain sensitivity, 
depression, and fatigue, which are common comorbidities asso-
ciated with many of these syndromes. These effects complicate 
efforts to exploit the Kyn pathway because beneficial therapeutic 
effects that suppress hyper-immunity and promote tolerance 
may come at the cost of increased pain, depression and fatigue, 
as consequences of therapy. Nevertheless, using IDO inducers to 
reduce disease-associated inflammation and hyper-immunity in 
the short term may attenuate innate IDO activity that promotes 
debilitating neurologic comorbidities. For example, in the EAE 
model of MS in mice, IDO activity was elevated in CNS tissues 
during EAE induction but STING agonists treatments to induce 
IDO in peripheral lymphoid tissues and suppress autoimmun-
ity abolished IDO1 expression in the CNS (30). Thus, overall 
beneficial effects in attenuating disease progression and reducing 
comorbidities may accrue from the diametric effects of IDO 
activity in distinct neuronal and lymphoid tissues. Furthermore, 
it may be possible to use drugs that modify the Kyn pathway 
to enhance production of immune suppressive Trp catabolites 
and reduce production of neurotoxic Trp catabolites. Thus, 
using HAAO inhibitors to block neurotoxic QA production 
and KATII inhibitors to promote immune suppressive HAA 
production may enhance therapeutic responses and reduce 
neurologic comorbidities, especially if combined with reagents 
that stimulate the Kyn pathway.
SUMMARY AnD FUTURe PROSPeCTS
Elevated IDO activity manifests in many settings of high clinical 
significance, driving substantial interest in manipulating IDO 
and the Kyn pathway for clinical benefit. Extensive research on 
mouse models of chronic inflammatory syndromes supports 
the hypothesis that IDO activity suppresses innate and adaptive 
immunity by depleting Trp and generating bioactive Trp catabo-
lites. Though IDO-mediated tolerogenic responses to sustained 
inflammation are particularly prominent, elevated IDO activity 
may also manifest rapidly to overcome co-induced immunogenic 
responses. It remains to be seen how many observations from 
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mouse models of clinical syndromes can be translated into clini-
cal practice. Promising initial results from recently completed 
or ongoing experimental clinical trials on cancer patients using 
several different IDO inhibitors will be the first potential clinical 
application to be tested fully. If outcomes support the use of IDO 
inhibitors in cancer, future research will focus on identifying 
optimal drug combinations to halt tumor growth and disrupt 
immune checkpoints in the widest range of patients, without 
stimulating autoimmunity or other toxic responses. Since 
immune checkpoints may also promote pathogen persistence 
and many infections induce IDO activity, there may also be 
opportunities to use IDO inhibitors to reduce pathogen bur-
dens and promote pathogen clearance in patients with chronic 
infections. However, more research is needed to understand the 
balance between anti-microbial and (host) tolerogenic effects of 
IDO, as the risk of inducing undesirable toxic effects is high until 
the role of IDO in specific chronic infections is elucidated fully. 
On the flip side, enhancing IDO activity as novel strategies to 
prevent or alleviate hyper-immune syndromes are supported by 
many proof-of-concept studies in mouse models of transplanta-
tion and AI syndromes. Translating these outcomes into clinical 
application will take some time, in part due to potential for many 
IDO inducing drugs to elicit tissue-damaging immunogenic 
responses as well as co-inducing tissue-protective tolerogenic 
responses. Thus, it may not be straightforward to satisfy ethical 
and corporate requirements for specific molecular targets driving 
unequivocal outcomes, unless more precise ways are found to 
manipulate the immune balance for clinical benefit. Finally, the 
combined immunologic and neurologic effects of bioactive Trp 
catabolites emphasizes the key roles of IDO and the Kyn pathway 
as drivers or regulators of many chronic conditions and common 
comorbidities, including pain depression and fatigue. Clearly, 
while more research is needed to understand the complex roles 
of IDO and the Kyn pathway in chronic diseases, the prospects 
are good for major novel insights and advances leading to clinical 
practice.
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